CSL Limited unit CSL Seqirus won a new contract with Canada’s Public Health Agency of Canada to support the country’s influenza pandemic preparedness plans. Under the agreement, CSL Seqirus will rapidly manufacture and deliver millions of doses of cell-based adjuvanted influenza vaccines if the World Health Organization declares an influenza pandemic, shifting from a prior egg-based vaccine arrangement.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSL Limited published the original content used to generate this news brief via CNW (Ref. ID: 202603060900CANADANWCANADAPR_C9073) on March 06, 2026, and is solely responsible for the information contained therein.
Comments